



United States Patent and Trademark Office





UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/462,218	05/22/2000	CHARLES POTTER	OPF10.02	4802
75	590 02/04/2003			
THOMAS P MCCRACKEN POWDERJECT PHARMACEUTICALS PLC FLOREY HOUSE OXFORD SCIENCE PARK			EXAMINER	
			SIRMONS, KEVIN C	
OXFORD, OX			ART UNIT	PAPER NUMBER
			3763	
			DATE MAILED: 02/04/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

.0)						
	Application No.	Applicant(s)				
Office Action Summan	09/462,218	POTTER ET AL.				
Office Action Summary	Examiner	Art Unit				
TI MANUAL DATE ALL INCOME IN COMMISSION OF THE C	Kevin C. Sirmons	3763				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	e correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	6(a). In no event, however, may a repty be within the statutory minimum of thirty (30) of ill apply and will expire SIX (6) MONTHS for cause the application to become ABANDO	timely filed days will be considered timely. om the mailing date of this communication. NED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on <u>02 L</u>	December 2002 .					
	s action is non-final.					
3) Since this application is in condition for allowa closed in accordance with the practice under a Disposition of Claims						
4)⊠ Claim(s) <u>1-5,8,13,14,19,21 and 22</u> is/are pend	ing in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-5,8,13,14,19 and 21</u> is/are rejected.						
7)⊠ Claim(s) <u>22</u> is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examiner						
10) The drawing(s) filed on is/are: a) accep						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language pro 15)☐ Acknowledgment is made of a claim for domesti	visional application has been r	eceived.				
Attachment(s)	o phoney andones of o.o.o. 33 1	www.vilW.VI limili				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Inform	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)				

Art Unit: 3763

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5, 8, 13, 14, 19, and 21 are rejected under 35 U.S.C. 102(b) as being anticipated by Drudik U.S. Pat. No. 5,125,892.

Drudik discloses a capsule adapted for containing a dose of a therapeutic agent to be delivered within a pressurized fluid flow, said capsule comprising a first member and a second member (14), wherein said first and second members are coupled together to provide a closed pocket (figs. 1 and 8-12) and one of said first and second members is moveable relative to the other member when a portion of said capsule is contacted with a pressurized fluid flow (figs. 1 and 8-12), said first and second members being constructed and arranged such that upon said relative movement a passage is formed through said capsule and said pocket is opened to expose the dose (figs. 1 and 8-12); as to claims 2-5, 8, 13, 14 and 21(figs. 1 and 8-12); as to claim 19, (col. 8).

Art Unit: 3763

Response to Amendment

Drawings

The drawings were objected to as failing to comply with 37 CFR 1.84(p)(4) because reference characters "33" and "34" had both been used to designate replaceable capsule.

Applicant has amended the drawings. Therefore, the objection has been withdrawn.

Claim Rejections - 35 USC § 112

Claims 3 and 4 was rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Applicant has clarified the 112 rejections by explanation. Therefore, the rejection has been withdrawn.

Response to Arguments

Applicant's arguments filed 12/2/02 have been fully considered but they are not persuasive.

In response to applicant's argument that Drudik fails to anticipate applicants' recited devices since it does not disclose each and every element thereof. In particular applicants' claim 1, which recites a capsule "comprising a first member and a second member, wherein said first and second member are coupled together to provide a closed pocket for containing the dose". It is the examiner's position that Drudik clearly discloses a first and a second member coupled together to provide a closed pocket for containing the dose (see figs. 1, 2, 3, and 8-12). In figure 1, a dose is clearly shown being contained by first and second members just below 14/36.

Art Unit: 3763

The dose could not be contained it 14/36 were not there to block the flow of the fluid. The above arguments also apply to claim 14.

Allowable Subject Matter

Claim 22 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communication from the examiner should be directed to Kevin C. Sirmons whose telephone number is (703) 306-5410. The examiner can normally be reached on Monday - Thursday from 6:30 am to 4:00 pm. The examiner can also be reached on alternate Fridays.

Art Unit: 3763

Kevin C. Sirmons Patent Examiner

5/22/02

BRIAN L. CASLER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700